Welcome to our dedicated page for Cytodyn SEC filings (Ticker: CYDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CytoDyn Inc. (CYDY) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a Delaware-incorporated, clinical-stage biotechnology and oncology company trading on the OTCQB, CytoDyn files a variety of documents that detail its clinical strategy, governance, capital structure, and material events.
Key filings for CYDY include current reports on Form 8‑K, which the company uses to report significant developments. Recent 8‑Ks describe an agreement in principle to settle a securities class action lawsuit, including the contemplated mix of cash and common stock, and a Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) that outlines terms under which CytoDyn may sell common stock over a multi‑year period. Another 8‑K and related proxy materials document stockholder approval of an amendment to increase the total number of authorized shares of common stock and the filing of a corresponding Certificate of Amendment in Delaware.
CytoDyn’s definitive proxy statement on Schedule DEF 14A provides additional insight into corporate governance, annual meeting agendas, advisory votes on executive compensation, auditor selection, and proposals related to share authorization. The proxy statement also explains how the company solicits votes, conducts virtual stockholder meetings, and structures its board elections.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping readers quickly understand complex legal and financial language. Real-time updates from EDGAR ensure that new 8‑Ks, proxy statements, and other reports appear promptly, while structured data makes it easier to track items such as amendments to the certificate of incorporation, equity financing arrangements, and outcomes of stockholder votes.
For investors analyzing CYDY, the SEC filings page is a primary source for understanding how CytoDyn manages its capital, responds to litigation, and formalizes decisions that affect shareholders, all grounded in the company’s official regulatory disclosures.
CytoDyn Inc. filed a preliminary S-3 prospectus to register for resale up to 120,000,000 shares of common stock by YA II PN, Ltd. under a Standby Equity Purchase Agreement dated November 3, 2025. CytoDyn is not selling securities under this prospectus and will not receive proceeds from YA’s resales. Shares issued to YA, if any, would be priced at 98% of the lowest daily VWAP over a three-trading-day pricing period following an Advance Notice, subject to conditions and limits.
The agreement permits CytoDyn, at its discretion, to sell shares to YA for up to $30.0 million in aggregate gross proceeds. Consideration to YA includes a 1,270,110-share commitment fee (1.00% of the commitment amount) and a $25,000 structuring fee. An Ownership Limitation of 4.99% applies. Common shares outstanding were 1,262,563,778 as of October 31, 2025, and would be 1,382,563,778 if all 120,000,000 shares were issued. CYDY last closed at $0.236 on October 31, 2025 on OTCQB.
CytoDyn Inc. entered a Standby Equity Purchase Agreement with Yorkville, giving the company the right for 36 months to sell common stock in periodic advances up to an aggregate $30,000,000, subject to conditions. Shares sold in any advance are priced at 98% of the lowest daily VWAP over a three‑day pricing period after an advance notice, within trading volume limits and other customary caps.
Yorkville’s ownership is limited to 4.99% of outstanding voting power at any time. Closing each advance requires an effective SEC registration statement covering the resale of the commitment shares and any advance shares. CytoDyn paid a $25,000 structuring fee and will pay a 1.00% commitment fee in common shares, half within five days and half at six months. Net proceeds from any sales are expected to be used for working capital and general corporate purposes, including repayment of debt.
CytoDyn, Inc. reported a quarterly filing that raises substantial doubt about its ability to continue as a going concern and notes that its consolidated financial statements omit any adjustments that might be necessary if the company is unable to continue. The company disclosed a reduced outstanding balance on a note to $35.4 million after partitioned notes and described prior conversions and exchanges that produced millions of shares of common stock, including approximately 7.5 million shares issued in one transaction and a cashless warrant exercise for 23.1 thousand shares.
The company disclosed significant equity plan activity: the Amended and Restated 2012 Equity Incentive Plan covered 79.3 million and 66.8 million shares at August 31, 2025 and May 31, 2025, respectively, with an automatic 1% evergreen increase on June 1, 2025. Stock-based compensation expense uses Black-Scholes with a weighted-average fair value of $0.26 per option for grants in the three months ended August 31, 2025. Operating lease costs were approx. $31.0 thousand for the quarter. The company is evaluating multiple FASB ASUs affecting disclosure and tax reporting with varying effective dates through December 15, 2027.
CytoDyn Inc. presents portions of its definitive proxy statement covering board composition, compensation committee duties, equity authorization and potential dilution. The board seeks authorization to issue additional shares of common stock to satisfy payment obligations in shares, to attract and retain management, scientific personnel and outside directors, and for future capital-raising needs. The company warns that additional issuances could dilute existing stockholders and that stockholders have no preemptive rights. The board states it does not currently plan material anti-takeover measures but notes authorized-but-unissued shares could be used to deter a takeover. Compensation committee policies include annual review of peer groups, engagement of independent advisors, avoidance of options grants while in possession of material nonpublic information, and limits on director bonuses tied to performance. The filing discloses transactions exceeding $120,000 involving insiders or major holders since June 1, 2023.
CytoDyn Inc.'s preliminary proxy statement describes items for stockholder consideration including approval of additional common stock authorization, board composition and governance and compensation committee practices. The company seeks authority to issue more shares to pay obligations in stock and to attract and retain key personnel and directors; it warns stockholders that future issuances may dilute ownership and that holders have no preemptive rights. The Board states any issuance would carry the same rights as existing common stock and that it will act in what it deems the company and stockholders' best interests. The proxy also outlines governance standards for independent directors and an annual compensation review process aided by independent advisors.